Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00036088

Enrollment

530

Registered

2002-05-08

Start date

2001-08-31

Completion date

2002-07-31

Last updated

2006-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia

Interventions

DRUGOlanzapine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

Inclusion: 1. You must be between the ages of 18 and 75. If you have reached your 76th birthday, you will not be able to participate 2. You must have been diagnosed with schizophrenia 3. You must be able to visit the doctor's office as scheduled for the next 7 months Exclusion: 1. You have a serious medical illness, such as heart, liver, or kidney disease (Note: If you are uncertain about a particular condition, discuss it with your doctor.) 2. You are either pregnant or breastfeeding

Countries

Argentina, Austria, Brazil, Germany, Ireland, Mexico, Peru, Puerto Rico, Spain, United Kingdom, United States, Venezuela

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026